Novartis, Kite Pharma Plan Regulatory Filings for CAR T Therapies
By
Novartis and Kite Pharma, a Santa Monica, California-based clinical-stage biopharmaceutical company, have both announced plans for filing applications seeking regulatory approval for their respective chimeric antigen receptor T-cell (CAR T)…
AstraZeneca Partners to Develop Bicyclic Peptides in $1 Billion-Deal
By
AstraZeneca has formed a collaboration with Bicycle Therapeutics, a Cambridge, UK-headquartered biotechnology company specializing in therapeutics based on its proprietary bicyclic peptide product platform in a deal worth more than…